Nutriband Inc. (NTRB)
Nasdaq · Healthcare · Biotechnology
$7.47+2.61%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $90.8M
- 52-week range
- $2.80 – $9.19
- 52-week change
- −4.72%
- EPS (trailing)
- −$0.53
Fiscal year to Jan 2026
- Revenue
- $2.0M (−4.80%)
- Net income
- −$8.2M
- Operating margin
- −408.4%
- Diluted EPS
- −$2.58
- Free cash flow
- −$5.1M
From the company’s annual report on SEC EDGAR.
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Headquarters: Orlando, United States · nutriband.com